| pubmed-article:20144493 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20144493 | lifeskim:mentions | umls-concept:C0019699 | lld:lifeskim |
| pubmed-article:20144493 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:20144493 | lifeskim:mentions | umls-concept:C0020517 | lld:lifeskim |
| pubmed-article:20144493 | lifeskim:mentions | umls-concept:C2720270 | lld:lifeskim |
| pubmed-article:20144493 | lifeskim:mentions | umls-concept:C0663655 | lld:lifeskim |
| pubmed-article:20144493 | lifeskim:mentions | umls-concept:C2926612 | lld:lifeskim |
| pubmed-article:20144493 | lifeskim:mentions | umls-concept:C0010181 | lld:lifeskim |
| pubmed-article:20144493 | lifeskim:mentions | umls-concept:C1708528 | lld:lifeskim |
| pubmed-article:20144493 | lifeskim:mentions | umls-concept:C0936012 | lld:lifeskim |
| pubmed-article:20144493 | lifeskim:mentions | umls-concept:C0037747 | lld:lifeskim |
| pubmed-article:20144493 | lifeskim:mentions | umls-concept:C0441704 | lld:lifeskim |
| pubmed-article:20144493 | pubmed:issue | 9 | lld:pubmed |
| pubmed-article:20144493 | pubmed:dateCreated | 2010-10-29 | lld:pubmed |
| pubmed-article:20144493 | pubmed:abstractText | Approximately 4% to 8% of patients with HIV-1 treated with abacavir present a hypersensitivity reaction (HSR). Various studies have shown a direct association between human leukocyte antigen (HLA)-B*5701 and HSR to abacavir. The objective of this study was to analyze whether systematic HLA-B*5701 testing to prevent HSR in patients treated with abacavir is a cost-effective option for the Spanish National Health System. | lld:pubmed |
| pubmed-article:20144493 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20144493 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20144493 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:20144493 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20144493 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20144493 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20144493 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20144493 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20144493 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:20144493 | pubmed:issn | 1578-1852 | lld:pubmed |
| pubmed-article:20144493 | pubmed:author | pubmed-author:Rivero-RománA... | lld:pubmed |
| pubmed-article:20144493 | pubmed:author | pubmed-author:Pérez-Escolan... | lld:pubmed |
| pubmed-article:20144493 | pubmed:author | pubmed-author:Nieves... | lld:pubmed |
| pubmed-article:20144493 | pubmed:author | pubmed-author:Calle-MartínO... | lld:pubmed |
| pubmed-article:20144493 | pubmed:author | pubmed-author:Iribarren-Loy... | lld:pubmed |
| pubmed-article:20144493 | pubmed:author | pubmed-author:García-Bujala... | lld:pubmed |
| pubmed-article:20144493 | pubmed:author | pubmed-author:Brosa-Riestra... | lld:pubmed |
| pubmed-article:20144493 | pubmed:copyrightInfo | Copyright © 2009 Elsevier España, S.L. All rights reserved. | lld:pubmed |
| pubmed-article:20144493 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:20144493 | pubmed:volume | 28 | lld:pubmed |
| pubmed-article:20144493 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20144493 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20144493 | pubmed:pagination | 590-5 | lld:pubmed |
| pubmed-article:20144493 | pubmed:meshHeading | pubmed-meshheading:20144493... | lld:pubmed |
| pubmed-article:20144493 | pubmed:meshHeading | pubmed-meshheading:20144493... | lld:pubmed |
| pubmed-article:20144493 | pubmed:meshHeading | pubmed-meshheading:20144493... | lld:pubmed |
| pubmed-article:20144493 | pubmed:meshHeading | pubmed-meshheading:20144493... | lld:pubmed |
| pubmed-article:20144493 | pubmed:meshHeading | pubmed-meshheading:20144493... | lld:pubmed |
| pubmed-article:20144493 | pubmed:meshHeading | pubmed-meshheading:20144493... | lld:pubmed |
| pubmed-article:20144493 | pubmed:meshHeading | pubmed-meshheading:20144493... | lld:pubmed |
| pubmed-article:20144493 | pubmed:meshHeading | pubmed-meshheading:20144493... | lld:pubmed |
| pubmed-article:20144493 | pubmed:meshHeading | pubmed-meshheading:20144493... | lld:pubmed |
| pubmed-article:20144493 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:20144493 | pubmed:articleTitle | Cost-effectiveness analysis of HLA-B*5701 typing in the prevention of hypersensitivity to abacavir in HIV+ patients in Spain. | lld:pubmed |
| pubmed-article:20144493 | pubmed:affiliation | Oblikue Consulting, Barcelona, Spain. diana.nieves@oblikue.com | lld:pubmed |
| pubmed-article:20144493 | pubmed:publicationType | Journal Article | lld:pubmed |
